The end-of-life experience for a cohort of patients with pulmonary arterial hypertension

Journal of Palliative Medicine

Volumn 15, Issue 10, 2012, Pages 1065-1070

  Grinnan, Daniel C ^a   Swetz, Keith Mark ^b   Pinson, Janet ^a   Fairman, Paul ^a   Lyckholm, Laurel J ^c   Smith, Tom ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN;

ADULT; ARTICLE; ATTITUDE TO ILLNESS; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; DESCRIPTIVE RESEARCH; DYSPNEA; FEMALE; HOSPICE; HUMAN; MALE; PALLIATIVE THERAPY; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PULMONARY HYPERTENSION; TERMINAL DISEASE;

COHORT STUDIES; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PALLIATIVE CARE; PROXY; TERMINAL CARE; VIRGINIA;

EID: 84866123796     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0085     Document Type: Article

References (21)

1. Humbert M, Sitbon O, Simmoneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
2. Hyduk A, Croft JB, Ayala C, Zheng K, Zheng ZJ, Mensah GA: Pulmonary hypertension surveillance - United States, 1980-2002. MMWR Surveill Summ 2005;54:1-28.
3. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon M: Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011;139: 1285-1293.
4. Wilkens H, Grimminger F, Hoeper M, Stä hler G, Ehlken B, Plesnila-Frank C, Berger K, Resch A, Ghofrani A: Burden of pulmonary arterial hypertension in Germany. Respir Med 2010;104:902-910.
5. Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D: Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: A systematic review and economic evaluation. Health Technol Assess 2009;13:1-320.
6. Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ: Phase II study: Integrated palliative care in newly diagnosed advanced non-small cell lung cancer patients. J Clin Oncol 2007;25:2377-2382.
7. Davidson PM, Paull G, Introna K, Cockburn J, Davis JM, Rees D, Gorman D, Magann L, Lafferty M, Dracup K: Integrated, collaborative palliative care in heart failure: The St. George heart failure service experience 1999-2002. J Cardiovasc Nurs 2004;19:68-75.
8. Goodlin SJ, Hauptman PJ, Arnold R, Grady K, Hershberger RE, Kutner J, Masoudi F, Spertus J, Dracup K, Cleary JF, Medak R, Crispell K, Pin a I, Stuart B, Whitney C, Rector T, Teno J, Renlund DG: Consensus statement: Palliative and supportive care in advanced heart failure. J Cardiol Failure 2004;10:200-209.
9. Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW, Heo DS: Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. Lung Cancer 2009;65: 242-246.
10. Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small cell lung cancer: Results of a randomized study of early palliative care. J Clin Oncol 2011; 29:2319-2326.
11. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K: The Edmonton Symptom Assessment System: A simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
12. Chang VT, Hwang SS, Feuerman M: Validation of the Edmonton Symptom Assessment Scale. Cancer 2000;88: 2164-2171.
13. Pritchard RS, Fisher ES, Teno JM, Sharp SM, Reding DJ, Knaus WA, Wennberg JE, Lynn J: Influence of patient preferences and local health system characteristics on the place of death. J Am Geriatr Soc 1998;46:1242-1250.
14. Higginson IJ, Sen-Gupta GJA: Place of care in advanced cancer: A qualitative systematic literature review of patient preferences. J Palliat Med 2000;3:287-300.
15. Barnato AE, Herndon MB, Anthony DL, Gallagher PM, Skinner JS, Bynum JP, Fisher ES: Are regional variations in end-of life care intensity explained by patient preferences? A study of the US Medicare population. Med Care 2007;45: 386-393.
16. Fadul NA, El Osta B, Dalal S, Poulter VA, Bruera E: Comparison of symptoms burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med 2008;11:422-427.
17. Morel T, Coyne PJ, Smith TJ: Prisoner of Modern Medicine: The New Dilemmas of Life-Extending Drugs Like Flolan. Presented at American Academy of Hospice and Palliative Medicine. February 2011.
18. Olsen ML, Swetz KM, Mueller PS: Ethical decision making with end-of-life care: Palliative sedation and withholding or withdrawing life-sustaining treatments. Mayo Clin Proc 2010;85:949-954.
19. Remme WJ, McMurray JJ, Rauch B, Zannad F, Keukelaar K, et al: Public awareness of heart failure in Europe: First results from SHAPE. Eur Heart J 2005;26:2413-2421.
20. Bain KT, Maxwell TL, Strassels SA, Whellan DJ: Hospice use among patients with heart failure. Am Heart J 2009;158:118-125.
21. Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS: The last six months of life for patients with congestive heart failure. J Am Geriatric Soc 2000;48(Suppl):S101-S109.